Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019

Схожие документы

• Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices
  по: Dhruva, Sanket S., et al.
  Опубликовано: (2017)
• Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011
  по: Rathi, Vinay K., et al.
  Опубликовано: (2020)
• Assessment of FDA Approval for New High-risk Therapeutic Devices Not Meeting Pivotal Study Primary End Points, 2016-2020
  по: Johnston, James L., et al.
  Опубликовано: (2021)
• Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements
  по: Zheng, Sarah Y., et al.
  Опубликовано: (2017)
• Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
  по: Skydel, Joshua J., et al.
  Опубликовано: (2019)